Scroll down
How do your AAV patients present?
Ears and auditory4,5
GPA>MPA
Hearing loss, ear ache
Eyes4, 5
GPA>>MPA
Red, painful eyes
Nose and sinuses2,4,5
GPA>>MPA
Saddle nose deformity,
nasal septum deformity,
sinusitis
Skin2,5
GPA>MPA
Rashes, purpura, lesions
Lungs and upper airways2,4–6
GPA>MPA
Coughing, pain, lung
nodules (seen in X rays),
alveolar haemorrhage
Nervous system2,4,5
CNS (GPA=MPA), PNS
(MPA>GPA)
Mononeuritis,
paraesthesia, other
peripheral neuropathy
Kidneys4,5
MPA>GPA
Blood in the urine
QoL impairment7
Similar to other chronic diseases and includes anxiety, fatigue, sleep disturbance, depression and pain
Ears and auditory4,5
GPA>MPA
Hearing loss, ear ache
Eyes4, 5
GPA>>MPA
Red, painful eyes
Nose and sinuses2,4,5
GPA>>MPA
Saddle nose deformity,
nasal septum deformity,
sinusitis
Skin2,5
GPA>MPA
Rashes, purpura, lesions
Lungs and upper airways2,4–6
GPA>MPA
Coughing, pain, lung
nodules (seen in X rays),
alveolar haemorrhage
Nervous system2,4,5
CNS (GPA=MPA), PNS
(MPA>GPA)
Mononeuritis,
paraesthesia, other
peripheral neuropathy
Kidneys4,5
MPA>GPA
Blood in the urine
QoL impairment7
Similar to other chronic diseases and includes anxiety, fatigue, sleep disturbance, depression and pain
There is a need for a new and more targeted approach to AAV (GPA/MPA) treatment8–11
AAV (GPA/MPA) is a severe, relapsing disease that can cause irreversible damage to multiple organs1-3
Despite treatment, many AAV patients do not achieve or sustain remission and the risk of relapse persists, further exacerbating organ damage12–14
Established therapies for AAV (GPA/MPA) have relied on non-specic immunosuppressants alongside
high-dose and/or long-term GCs, which add to the burden of disease11,14–18
Activation of the alternative complement pathway plays a key role in AAV and no established therapies address this key driver of vascular inflammation9,11,19
See how AAV impacts your patients
and to hear real life
patient experiences
For more information on the
burden of AAV and the
mechanism of disease
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; CNS, central nervous system; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MOA, mechanism of action; MPA, microscopic polyangiitis; PNS, peripheral nervous system; QoL, quality of life.
References
1. Wallace ZS, Miloslavsky EM. BMJ 2020;368:m421. 2. Pagnoux C. Eur J Rheumatol 2016;3(3):122–33. 4. Al Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34. 4. Hunter RW, et al. BMJ 2020;369:m1070. 5. Kitching AR, et al. Nat Rev Dis Primers 2020;6(1):71. 6. Quartuccio L, et al. J Autoimmun 2020;108:102397. 7. Basu N, et al. Ann Rheum Dis 2014;73(1):207–11. 8. Hutton HL, et al. Semin Nephrol 2017;37(5):418–35. 9. Jennette JC, Nachman PH. Clin J Am Soc Nephrol 2017;12(10):1680–91. 10. Bekker P, et al. PLoS One 2016;11(10):e0164646. 11. Lamprecht P, et al. EMJ Rheumatol 2021;8(1):36–42. 12. Stone JH, et al. N Engl J Med 2010;363(3):221–32. 13. Specks U, et al. N Engl J Med 2013;369(5):417–27. 14. Robson J, et al. Rheumatology (Oxford) 2015;54(3):471–81. 15. Yates M, et al. Ann Rheum Dis 2016;75(9):1583–94. 16. Little MA, et al. Ann Rheum Dis 2010;69(6):1036–43. 17. McGregor JG, et al. Clin J Am Nephrol 2012;7(2):240–7. 18. Turnbull J, Harper L. Best Pract Res Clin Rheumatol 2009;23(3):391–401. 19. Liberman AC, et al. Front Endocrinol (Lausanne) 2018;9:235